News Sentiment

ANAB sentiment intelligence

AnaptysBio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 66.39 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+4.7% over one week, +18.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

AnaptysBio (NASDAQ:ANAB) Trading 5.3% Higher - Should You Buy?

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 4.7% Price confirming higher
Trend fit Trend active 18.4% over four weeks
Fair value 205.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 34
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 17
TradingView 9
Stock Titan 6
MarketBeat 5
simplywall.st 4
Sahm 2
Investing.com Nigeria 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 14
Analyst action 8
Balance sheet 1
Regulatory and legal 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Sahm Direct company coverage

Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial?

AnaptysBio (ANAB) is drawing attention due to potential royalty income from the cancer drug Jemperli and an upcoming trial with GSK, contributing to significant long-term share price gains despite recent volatility. With analysts suggesting a fair value of $90 against a current p

Tone
Positive 65/100
Event
Market update
Published
16 Jul 2026 10:41
Source
Sahm
GuruFocus Direct company coverage

Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10%

AnaptysBio (ANAB) shares fell by 10.8% on July 15, 2026, closing at $55.76, amidst broader market volatility and investor caution in the biotechnology sector. The company, a clinical-stage biotech developing antibody product candidates, has a market capitalization of $1.67 billio

Tone
Negative 20/100
Event
Market update
Published
15 Jul 2026 15:16
Source
GuruFocus
MarketBeat Direct company coverage

AnaptysBio (NASDAQ:ANAB) Shares Down 7% - Time to Sell?

AnaptysBio (NASDAQ:ANAB) shares dropped 7% in Tuesday trading, hitting an intraday low of $65.76. Despite a wider-than-expected Q1 loss, analysts maintain a "Moderate Buy" rating with an average price target of $81.82, and the company has authorized a $100 billion stock repurchas

Tone
Negative 38/100
Event
Analyst action
Published
14 Jul 2026 18:11
Source
MarketBeat
Investing.com Nigeria Direct company coverage

Form 144 ANAPTYSBIO For: 13 July By Investing.com

This article reports on a Form 144 filing for ANAPTYSBIO on July 13. It is a brief, factual announcement from Investing.com, providing no additional details beyond the filing date and company name. The article's content is minimal, serving primarily as an informational update.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 22:12
Source
Investing.com Nigeria
Stock Titan Direct company coverage

AnaptysBio (NASDAQ: ANAB) insider files to sell 10,694 shares after option exercise

JOE ANTHONY WARE, an insider at AnaptysBio (ANAB), has filed a Form 144 to sell 10,694 shares of common stock with an aggregate market value of $718,333.09. These shares are related to a stock option exercise and are expected to be sold on or after July 13, 2026, on NASDAQ. This

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:41
Source
Stock Titan
MarketBeat Direct company coverage

AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has received a "Moderate Buy" consensus recommendation from thirteen brokerages, with an average 12-month price target of $81.82. Analyst ratings have been mixed, with some price target increases and some downgrades, indicating ongoing debate about

Tone
Neutral 50/100
Event
Analyst action
Published
10 Jul 2026 06:39
Source
MarketBeat
Simply Wall Street Direct company coverage

Should AnaptysBio’s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base?

AnaptysBio (ANAB) was removed from several Russell indices in June 2026, which may impact its short-term trading liquidity and passive fund ownership. Despite this, the core investment thesis remains centered on its immunology pipeline and collaborations, with ongoing litigation

Tone
Negative 42/100
Event
Balance sheet
Published
08 Jul 2026 05:11
Source
Simply Wall Street
TradingView Direct company coverage

AnaptysBio, Inc. Financial Disclosures & Filings

This page provides a comprehensive list of AnaptysBio, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategic decisions. It highlights key events such as earnings reports, corporate presentations, and conference transcr

Tone
Positive 75/100
Event
Earnings
Published
01 Jul 2026 21:09
Source
TradingView
Stock Titan Direct company coverage

[144] ANAPTYSBIO, INC SEC Filing

This article details an SEC Form 144 filing by AnaptysBio, Inc. (ANAB) concerning a proposed sale of securities. The document indicates a neutral filing impact and sentiment, outlining the filer and issuer information, as well as details about the common stock to be sold by Morga

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 09:40
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of AnaptysBio, Inc. – NASDAQ:ANAB

This article provides the enterprise value to revenue forward for AnaptysBio, Inc. (NASDAQ: ANAB). It presents a financial metric related to the company's valuation, indicating its enterprise value relative to its future anticipated revenue. The information is sourced from Tradin

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 23:10
Source
TradingView
Simply Wall Street Direct company coverage

Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus?

AnaptysBio (ANAB) was recently removed from several Russell indices and entered a one-year sublease agreement for its San Diego facility. These actions suggest a strategic shift involving optimized real estate commitments and a reframing of its investment narrative. Investors sho

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 15:10
Source
Simply Wall Street
TradingView Direct company coverage

Price to book forward of AnaptysBio, Inc. – NASDAQ:ANAB

The article focuses on the "Price to book forward" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It provides a view of this financial indicator on the TradingView platform, noting that the market is closed and no trades have occurred for the stock.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 11:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of AnaptysBio, Inc. – NASDAQ:ANAB

The article provides the "Enterprise value to EBITDA forward" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It appears to be a financial data snippet from TradingView, which offers various market tools and data for stocks, including detailed financial information.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:10
Source
TradingView
Investing.com South Africa Direct company coverage

Form 144 ANAPTYSBIO For: 29 June By Investing.com

This article announces the filing of Form 144 for ANAPTYSBIO (ANAB) on June 29. Form 144 is filed with the SEC when company insiders intend to sell restricted or controlled securities. The article provides the title, date, and company, indicating a standard regulatory filing noti

Tone
Positive 59/100
Event
Regulatory and legal
Published
29 Jun 2026 23:10
Source
Investing.com South Africa
Stock Titan Direct company coverage

Affiliate plans to sell 9,476 ANAB shares (NASDAQ: ANAB)

An affiliate of ANAPTYSBIO, INC (NASDAQ: ANAB) has filed a Form 144 to sell 9,476 shares acquired via a stock option exercise on June 29, 2026. The filing also details multiple common stock dispositions by Dennis Mulroy throughout May and June 2026, including specific share count

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

AnaptysBio (NASDAQ: ANAB) proxy details director votes and equity plan limits

AnaptysBio (NASDAQ: ANAB) is holding its annual stockholders meeting on August 11, 2026, where key items for vote include the election of two Class III directors, ratification of KPMG LLP as the auditor, an advisory Say-on-Pay vote for executive compensation, and an amendment to

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of AnaptysBio, Inc. – NASDAQ:ANAB

This page provides financial information for AnaptysBio, Inc. (NASDAQ: ANAB), specifically focusing on its forward price-to-earnings ratio. It appears to be a financial data page from TradingView, offering an overview of the company's financials, news, and other market data.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 12:41
Source
TradingView
www.marketscreener.com Direct company coverage

AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell Microcap Index

AnaptysBio, Inc. (ANAB) has been removed from the Russell Microcap Index. The company's recent activities include a change in its fiscal year-end, UBS adjusting its price target to $76 with a Buy rating, and reporting earnings for Q1 2026. AnaptysBio also recently appointed Chris

Tone
Negative 38/100
Event
Analyst action
Published
29 Jun 2026 08:39
Source
www.marketscreener.com
Sahm Direct company coverage

AnaptysBio (ANAB) Draws Valuation Attention, Is The Market Already Pricing In Future Growth?

AnaptysBio (ANAB), a clinical stage biotech company, is drawing attention with its recent performance and current valuation. While its 7.3x Price-to-Sales ratio appears undervalued compared to industry peers, an estimated fair P/S ratio suggests it might be overvalued. A Discount

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 07:10
Source
Sahm
Investing.com Nigeria Direct company coverage

Form 144 ANAPTYSBIO For: 26 June By Investing.com

Investing.com reported on a Form 144 filing for ANAPTYSBIO on June 26, 2026. The article primarily consists of the headline repeated several times and a timestamp, with no further details about the filing itself. It is surrounded by various market data, news headlines, and naviga

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

ANAB (NASDAQ) insider sells 10,000 shares; Mulroy made multiple May–June sales

A recent SEC Form 144 filing indicates an insider sale of 10,000 ANAB shares through a stock option exercise on June 26, 2026. The filing also details multiple prior sales by Dennis Mulroy in May and June 2026, including 35,000 shares for $1,848,750 and 20,000 shares for $1,153,0

Tone
Negative 38/100
Event
Market update
Published
26 Jun 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

ANAB Forecast — Price Target — Prediction for 2027

This article provides a forecast for AnaptysBio, Inc. (ANAB) stock, including its current price of 64.75 USD, recent performance trends, and analyst price targets. Eight analysts have provided 1-year price forecasts, with a maximum estimate of 95.00 USD and a minimum of 70.00 USD

Tone
Positive 67/100
Event
Analyst action
Published
26 Jun 2026 19:41
Source
TradingView